💊 ACE inhibitor · First-dose hypotension & airway risk

Ramipril: Nursing Drug Guide, First-Dose Hypotension & NCLEX Review

ALTACE lowers blood pressure and supports cardiovascular prevention after myocardial infarction, but nurses must guard against first-dose hypotension when diuretics overlap or post-MI dosing starts—labeling requires two hours of supervised observation after the first post-MI dose—plus angioedema (higher reported incidence in Black patients), hyperkalemia when potassium supplements or salt substitutes overlap, and acute renal injury with NSAIDs or volume depletion. Discontinue immediately when pregnancy is detected.

⏱️15 min read

📅Updated May 31, 2026

✓Pharmacist Reviewed

✍️

Written by

Sid A. Abdala Balal

🧪

Reviewed by

Kim Serra

Pharmacist

🚨 Major safety note — First-dose hypotension, fetal toxicity, angioedema, and potassium

The ALTACE boxed warning states that when pregnancy is detected, ramipril should be discontinued as soon as possible because drugs acting on the renin–angiotensin system can injure or cause death of the developing fetus. Separately, excessive blood pressure reduction occurs most often after the first dose—especially with diuretics, volume depletion, or renal artery stenosis—and post-MI heart failure initiation requires at least two hours of supervised observation after the first dose. Angioedema of the face, lips, tongue, glottis, or larynx—including fatal cases—has occurred with ACE inhibitors at any time during treatment, with a higher rate in Black than non-Black patients; discontinue immediately and escalate airway care when breathing is threatened. Serum potassium and renal function need periodic surveillance because RAS blockade predisposes to hyperkalemia (serum K⁺ >5.7 mEq/L in about 1% of hypertensive patients per labeling) and acute renal failure, particularly with dehydration, NSAIDs, potassium supplements, potassium-sparing diuretics, or dual RAS inhibition.

📋 Contents

⚡ Quick facts

💊

Class

ACE inhibitor (prodrug of ramiprilat)

➡️

Route

Oral capsule

📐

Usual adult start

2.5 mg daily (1.25 mg with diuretic)

⚠️

Main risks

First-dose hypotension · angioedema · K⁺

💡 Key takeaway

Before every ramipril dose—especially the first post-MI dose—reconcile volume status, diuretic overlap, and whether supervised observation is ordered; then screen for airway-threatening swelling and potassium/renal trends that can turn a routine capsule into a hypotension or hyperkalemia emergency.

💊

Most common brand names

Ramipril is the generic name for this angiotensin-converting enzyme inhibitor. The primary U.S. brand is ALTACE; fixed-dose combinations with thiazide-type diuretics are also marketed. Trace both active ingredients through medication reconciliation rather than trusting look-alike bottle labels.

🎯

Why we give it — Indications

ALTACE prescribing information approves ramipril for hypertension in adults, to reduce the risk of myocardial infarction, stroke, and death from cardiovascular causes in high-risk patients (HOPE trial population), and as treatment of heart failure following acute myocardial infarction. Nurses on medical–surgical and cardiac units most often administer the once-daily antihypertensive capsule; telemetry and step-down teams manage post-MI pathways with supervised first-dose observation per heart attack protocols.

Use	Detail
Hypertension	Lowers blood pressure; may combine with thiazide-type diuretics when monotherapy is insufficient.
CV risk reduction (HOPE)	2.5 mg daily titrated to 5 mg then 10 mg daily in patients at high risk without heart failure or low ejection fraction.
Post-MI heart failure	2.5 mg twice daily after hemodynamic stabilization; first dose requires at least two hours of supervised observation per labeling.

On a small screen, swipe or scroll sideways to see the full table.

🔬

How it works

Ramipril is an oral prodrug converted in the liver to the active ACE inhibitor ramiprilat, which suppresses angiotensin II formation and aldosterone secretion, producing vasodilation with modest serum potassium rises. ACE also degrades bradykinin; whether elevated bradykinin contributes both to blood pressure lowering and to nuisance dry cough is discussed in labeling and overlaps mechanistically with angioedema vigilance pathways.

📐

Dosing overview

Doses below reflect the reviewed ALTACE label; titrate strictly to clinician orders and to blood pressure plus renal-electrolyte response. Estimated GFR informs starting dose selections described in prescribing information.

Hypertension (no diuretic)

2.5 mg once daily

Usual range 2.5–20 mg/day in one or two divided doses

Hypertension (diuretic / volume depleted / RAS)

1.25 mg once daily

Minimize hypotension by stopping diuretic temporarily, increasing salt intake, or reducing ramipril start per labeling

CV prevention (HOPE)

2.5 → 5 → 10 mg daily

Titrate at prescriber-defined intervals when tolerated

Post-MI heart failure

2.5 mg twice daily

At least 2 h supervised observation after first dose; titrate toward 5 mg BID (~3 weeks between increases); reduce to 1.25 mg BID if hypotensive

Renal impairment (HTN)

1.25 mg daily

Maximum 5 mg/day when creatinine clearance is reduced

Renal impairment (post-MI HF)

1.25 mg daily

May increase up to 2.5 mg twice daily when tolerated

⏱️

Onset, peak, duration, and half-life

Parameter	Value	Nursing relevance
Absorption / onset	Peak plasma ramipril within ~1 h; converted to ramiprilat with peak ~3 h; antihypertensive effect begins within 1–2 h	First-dose hypotension risk peaks when diuretics continue—align orthostatic vitals with MAR timing, especially post-MI first dose
Peak / half-life	Effective ramiprilat half-life ~13–17 h; once- or twice-daily dosing per indication; food does not materially alter absorption	Once- or twice-daily scheduling per order; capsules may be opened and sprinkled on applesauce per labeling
Elimination	Primarily renal excretion of metabolites; accumulation when GFR is reduced; hemodialysis removal of ramipril not established per labeling	Renal impairment and dialysis timing affect drug levels—coordinate pharmacy when creatinine rises

On a small screen, swipe or scroll sideways to see the full table.

🛡️

Before you give it — Safety check

Pretreatment checks

Identify pregnancy possibilities in patients of reproductive potential and verify contraceptive or testing plans with prescribing teams
Review baseline and recent renal function trajectory—especially when starting therapy, escalating dose, restarting after illness, or adding nephrotoxic or hyperkalemia-provoking drugs
Screen for hypersensitivity or prior ACE inhibitor angioedema per contraindications language
Confirm interacting agents: NSAIDs, potassium supplements, potassium-sparing diuretics (for example spironolactone), dual RAS-blocking regimens (losartan or ARB combos), neprilysin inhibitors, lithium, mTOR inhibitors, intensified antidiabetic therapy predisposing hypoglycemia

Contraindications (FDA label summary)

Hypersensitivity to ramipril or another ACE inhibitor
History of angioedema including hereditary or idiopathic angioedema
Combination with neprilysin inhibitor (example sacubitril)—do not start ramipril within 36 hours of switching from sacubitril/valsartan and vice versa
Concurrent aliskiren with ACE inhibitors in patients who have diabetes

Important interactions

Drug / scenario	Effect	Nursing action
furosemide, thiazide diuretics	Excessive blood pressure drops—especially shortly after initiating or escalating diuretics	Take orthostatic vitals closely first two weeks; escalate symptomatic hypotension or oliguria
Potassium-retaining therapies	Combined aldosterone suppression plus spironolactone-type agents or supplementation elevates hyperkalemia incidence	Ensure scheduled BMP follow-up; hold scheduled dose when clinically ordered for critical lab abnormalities pending prescriber contact
ibuprofen / COX-2 inhibitors	Reduced antihypertensive effect plus worsened renal impairment risk	Educate OTC avoidance without prescriber review; monitor serum creatinine and blood pressure when short courses are unavoidable
Dual RAS inhibition	Higher renal dysfunction, hypotension, and potassium disturbances	Scrutinize inpatient lists for simultaneous ACE, ARB, or direct renin blocker combinations; involve pharmacy early

On a small screen, swipe or scroll sideways to see the full table.

➡️

Administration

ALTACE capsules: 1.25, 2.5, 5, and 10 mg; swallow whole or open and sprinkle contents on a small amount (about 4 oz) of applesauce per labeling—swallow without chewing
May be taken with or without food per labeling
Once- or twice-daily dosing per indication—post-MI heart failure uses twice-daily 2.5 mg with supervised first-dose observation
Ramipril is oral only on typical med-surg units—do not substitute IV ACE inhibitor formulations on the MAR

📈

Expected therapeutic response

Blood pressure declines within 1–2 hours of dosing with sustained antihypertensive effect over 24 hours when once-daily dosing is used per labeling
Combination with thiazide diuretics may blunt concurrent hypokalemia versus diuretics alone owing to tempered aldosterone signals
Patients with heart failure after MI should articulate improved exercise tolerance when hypotension-mediated symptoms are absent

🚨

Red flags — Stop and act

Progressive airway-compromising lip swelling, tongue fullness, muffled speech, inspiratory difficulty—assume ACE inhibitor angioedema requiring immediate pathway activation
Serum potassium climbing trend even before critical numeric threshold—coordinate repeat testing and cessation of potassium introductions
New oliguria, dizziness, syncope, or collapsing perfusion pressures after initiating therapy or restarting post-acute illness—especially within two hours of first post-MI dose
Creatinine elevations suggesting acute kidney injury attributable to RAS suppression, volume depletion, or renovascular physiology
Life-threatening anaphylactoid reactions during high-flux dialysis or hymenoptera desensitization described in prescribing information—stop procedure per protocol and activate resuscitation resources

⚠️

Adverse effects

Adverse effect	Frequency / context	Nursing response
dizziness, headache, cough	Hypertension trials: headache 5.4%, dizziness 2.2%, fatigue 2.0% (possibly/probably related); cough led to discontinuation in about 1% per labeling	Teach positional caution after first doses—especially post-MI supervised dosing; distinguish dry cough from angioedema; hold and escalate symptomatic hypotension
Hyperkalemia	Serum K⁺ >5.7 mEq/L in about 1% of hypertensive patients per labeling; higher with potassium-raising drugs	Trend serum potassium; hold and notify when clinically significant per protocol
Intestinal angioedema	Abdominal pain with or without nausea/vomiting; may occur without prior facial swelling	Stop ACE inhibitor; notify prescriber; do not dismiss as benign GI upset

On a small screen, swipe or scroll sideways to see the full table.

☠️

Overdose management

ALTACE overdosage data in labeling describe animal studies at very high doses. In humans, the most likely manifestation is hypotension; there is no specific reversal agent cited.

Recommended supportive therapies (label)

Intravenous normal saline infusion for hypotension
Angiotensin II infusion is theoretically beneficial but is not available per labeling
Hemodialysis removal of ramipril is not established per prescribing information
Supportive perfusion, airway, and electrolyte monitoring per institutional toxicology protocol
Consult local poison control / toxicology services per facility protocol when ingestion amount or intent is uncertain

⚠️Poisoning services

Consult local poisoning or toxicology services per institutional policy when intentional overdose or uncertain ingestion volume is reported—even though labeling describes no reversal agent analogous to opioid or acetaminophen pathways.

🔤

Look-alike / sound-alike and error prevention

ALTACE / ramipril versus enalapril / lisinopril / benazepril: ACE inhibitor names and capsule colors vary by manufacturer—barcode every dose
Ramipril versus ramipril–HCTZ combination: confirm whether order references monotherapy versus fixed combination inadvertently duplicated elsewhere
Strength jumps: 1.25, 2.5, 5, and 10 mg capsules sit adjacent in ADCs—witness high-risk strengths
Capsule sprinkle versus whole swallow: verify MAR instructions when patients cannot swallow intact capsules

🛏️

Practical bedside notes

Topic	Bedside guidance
Capsule administration	Swallow whole or open and sprinkle on applesauce per labeling—do not chew sprinkled contents.
Meal pairing	Food does not materially change exposure—steady daily timing assists vitals and symptom tracking.
Orthostatics	Volume-depleted patients and post-MI first doses merit lying-standing blood pressure during initial therapy per labeling hypotension warnings.
Post-MI observation	First post-MI dose requires at least two hours of supervised monitoring for hypotension per ALTACE labeling.
Salt substitutes	Potassium-containing substitutes can precipitate hyperkalemia on ACE inhibitors—teach patients to read labels and ask before buying.

On a small screen, swipe or scroll sideways to see the full table.

👥

High-risk populations

Population	Considerations
Pregnancy	ALTACE labeling links second- and third-trimester fetal injury to renin-angiotensin inhibition (renal hypoperfusion, oligohydramnios-related complications, neonatal renal dysfunction). Nursing priority is cessation as soon as pregnancy is recognized.
Renal artery stenosis / volume depletion	Patients whose renal perfusion depends on angiotensin II may develop abrupt creatinine rises, oliguria, or first-dose hypotension when ACE inhibition starts—coordinate hold rules with nephrology or cardiology.
Post-MI initiation	First dose 2.5 mg BID requires at least two hours of supervised observation; hypotension is most common after the first dose per labeling.
Black ancestry monotherapy caveat	Labeling notes smaller average antihypertensive response with ACE monotherapy in Black patients and higher angioedema incidence—prioritize airway teaching regardless of BP response.
Lactation	ALTACE labeling states ramipril should not be used in nursing mothers because of potential for serious adverse reactions in breastfed infants. LactMed notes limited human data—individualized prescriber discussion when breastfeeding cannot be avoided.
type 2 diabetes	Labeling warns increased hypoglycemia risk when antidiabetic medicines overlap—monitor glucose especially during the first month of combined use.

On a small screen, swipe or scroll sideways to see the full table.

📊

Monitoring and documentation

Monitor

Blood pressure, heart rate, and hydration status after initiation, dose increases, and restarts following intercurrent illness—use proper blood pressure measurement technique after first-dose hypotension risk
Trend serum creatinine, eGFR, and electrolytes on the basic metabolic panel, including potassium
Distinguish nuisance dry cough from progressive inspiratory distress, voice change, or lip or tongue fullness that may signal airway angioedema
Blood glucose when antidiabetic therapy runs concurrently—labeling notes increased hypoglycemia risk with antidiabetic medicines

Document

Dose, route, time, indication, blood pressure, orthostatic symptoms, OTC NSAID use, and potassium supplements or salt substitutes
Patient education on pregnancy avoidance, angioedema warning signs, dehydration risk, and hypoglycemia vigilance when diabetes medicines overlap
Prescriber/pharmacist notifications, hold decisions, rapid response or airway interventions, and repeat lab trends

💬

Patient teaching

Discuss pregnancy planning—stop ramipril as soon as pregnancy is suspected or confirmed per the boxed warning
Teach that facial swelling, lip or tongue swelling, noisy breathing, or swallowing difficulty means stop the drug and seek emergency care immediately—do not take another dose
Do not start potassium supplements or potassium-containing salt substitutes without prescriber approval
Report light-headedness, especially when standing; vomiting, diarrhea, heat exposure, and dehydration increase hypotension risk during early therapy
Patients with diabetes should monitor glucose more closely when ACE inhibitors are added
Check with the care team before starting OTC NSAIDs such as ibuprofen—combined use can worsen renal function and blunt blood pressure control

✋

The Hold Rule

Hold (clinician-aligned) dosing and escalate when:

✋Hold ramipril (ALTACE) — pause and escalate

Pregnancy confirmed or suspected—discontinue immediately and notify the prescriber for obstetric follow-up
Angioedema or any airway-threatening swelling of the face, lips, tongue, or throat—hold and escalate per emergency protocol
Symptomatic first-dose or post-MI hypotension, syncope, or shock until volume status and orders are reviewed
Hyperkalemia, oliguria, or rising creatinine after dehydration, NSAID use, or dual RAS-blocking therapy—hold and clarify with prescriber/pharmacist
Prohibited combinations on the MAR (dual RAS blockade, aliskiren with ACE inhibitor in diabetes, neprilysin inhibitor within 36-hour switch window, or suspected lithium toxicity)

🩺

Clinical practice integration and workflow

1. Stewardship checkpoints

Barcode verify ramipril/ALTACE capsule strength before every administration pass
Pair blood pressure captures with electrolyte renal panels after therapy starts or adjunct drugs change—especially post-MI first doses
Screen admission medication lists for OTC renal stressors and undocumented diuretic overlap before first ramipril dose

2. High-alert designation

Not universally classified institutional high-alert

Treat ramipril with proportional vigilance analogous to high-stakes cardiometabolic meds because fetal catastrophe, first-dose hypotension, airway angioedema, and renal failure potentials exceed ordinary oral antihypertensive error tolerance.

3. Hold and question cues

New tongue thickness, lip asymmetry, or vocal changes—assume ACE inhibitor airway emergency until clarified
Symptomatic hypotension within two hours of first post-MI ramipril dose—hold and escalate per supervised observation protocol
Creatinine jump ≥30% or institution-defined thresholds after RAS initiation mandates hold clarification per policy

Teach-back prompts

“What should you expect during the first two hours after your first post-MI ramipril dose?” (Patient should articulate supervised monitoring, lying down if dizzy, and reporting light-headedness immediately.)
“Which swelling symptoms mean you skip further doses tonight?” (Patient should articulate face, lip, tongue, or airway difficulty and emergency activation.)

Pharmacist collaboration: Neprilysin sacubitril/valsartan transition windows NSAID unavoidable courses lithium dosing potassium binder coordination breastmilk counselling.

Prescriber / specialist: Resistant hypertension dialysis membrane planning angioedema recurrence pregnancy confirmation hyperkalemia refractory escalating renal insults unexplained hepatic enzyme cholestasis alerts.

🧠 Quick mental checklist

First-dose hypotension—is blood pressure stable after post-MI supervised observation window?
Airway—is there progressing lip, tongue, or voice change after today’s ramipril doses?
Renal trajectory—Scr, potassium, and volume status fair?
Pregnancy possibility documented and contraception counseling complete?
New NSAID, potassium supplementation, or salt substitutes reviewed?

📚

Ramipril NCLEX practice questions

Rehearse NCLEX-style clinical judgment practice for ramipril: use the case tabs (MAR, Labs, Vitals, Nursing notes) to judge post-MI first-dose hypotension, supervised observation requirements, SATA cue recognition, potassium/creatinine trend SATA, urgency matrix sorting, diuretic starting-dose MCQ, and overdose cloze focused on hypotension without a labeled antidote or established hemodialysis removal.

Select a tab to view MAR, labs, vitals, and nursing note details for this case.

Medication administration record

Ramipril 2.5 mg PO — first dose due now (post-MI heart failure pathway)
Furosemide 40 mg IV daily — given 0600
Aspirin 81 mg, atorvastatin 80 mg, metoprolol tartrate per cardiology protocol

Question 1 — Priority action

After reviewing the MAR, labs, vitals, and nursing notes tabs, what is the nurse’s best FIRST action before the scheduled first post-MI ramipril dose?

Administer ramipril 2.5 mg immediately because troponin is trending down Hold ramipril, notify prescriber/pharmacist about borderline hypotension, light-headedness, diuretic overlap, and low urine output; initiate supervised observation protocol before any dose Give ramipril and double the furosemide dose to clear pulmonary edema faster Skip supervised observation because potassium is normal on the morning BMP

Question 2 — Recognize cues

Which cues from this unfolding post-MI case raise first-dose hypotension concern before giving ramipril? After reviewing the case tabs…

Select all that apply

Sitting BP 102/64 mm Hg with reported light-headedness when sitting up Patient denies lip swelling at current assessment Furosemide given this morning with urine output 180 mL since 0600 Dry mucous membranes and 1.8 kg weight loss since admission Potassium 4.3 mEq/L without ECG changes

Question 3 — Trend interpretation

Ninety minutes after the first ramipril dose (supervised observation ongoing), updated documentation shows:

Trend snapshot
BP 88/52 mm Hg sitting; patient dizzy and diaphoretic
HR 102; urine output unchanged; IV normal saline infusing per protocol
Potassium 4.2 mEq/L; creatinine 1.2 mg/dL

Select all nursing actions aligning with symptomatic first-dose hypotension.

Hold further ramipril doses and notify prescriber/pharmacist immediately Continue scheduled ramipril and encourage ambulation to raise blood pressure Maintain supervised monitoring, repeat orthostatic vitals, and document perfusion response to IV fluids Reassess volume status, intake/output, and diuretic timing with the care team Document hypotension as an evaluate-outcomes finding within the supervised observation window

Question 4 — Matrix judgment

After reviewing MAR, laboratories, vitals, and nursing narratives for ramipril therapy, categorize each bedside finding’s urgency.

Finding	Expected — document and continue monitoring	Requires follow-up — notify prescriber/pharmacist	Urgent — immediate escalation
Month-four stable therapy; intermittent dry cough; airway patent; normal voice
First post-MI dose: BP 92/58 mm Hg with dizziness; prescriber not yet aware
Progressive tongue swelling with inspiratory stridor after evening ramipril dose
K⁺ 5.6 mEq/L with new muscle weakness on ramipril plus potassium salt substitute

On a small screen, swipe or scroll sideways to see the full table.

Question 5 — First dose with diuretic

A 72-year-old with hypertension is starting ramipril today while continuing furosemide 20 mg each morning. Which starting dose and monitoring plan best reflects ALTACE labeling?

Begin 2.5 mg ramipril unsupervised at bedtime because diuretics are taken in the morning Begin 1.25 mg ramipril once daily with close blood pressure and volume-status monitoring; consider temporarily stopping or reducing the diuretic per prescriber when feasible Hold ramipril until potassium exceeds 6.5 mEq/L regardless of blood pressure Stop furosemide independently and start 10 mg ramipril for faster control

Question 6 — Overdose management

ALTACE overdosage information highlights absent specific reversal drug—expect predominant while monitoring perfusion, electrolytes, and airway status per protocol.

Answer key & rationale

Next step Timed NCLEX Next Gen–style scenarios on NurseOnShift

❓

Frequently asked questions

💬FAQ

▼

What should I check before giving ramipril?

Review the latest basic metabolic panel (especially potassium and creatinine), confirm blood pressure and orthostatic symptoms, verify pregnancy status in patients of childbearing potential, scan the MAR for potassium supplements or potassium-containing salt substitutes, potassium-sparing diuretics, NSAIDs, lithium, dual renin-angiotensin system blockade, and neprilysin inhibitors, and match capsule strength (1.25–10 mg) to the order. After post-MI initiation, confirm supervised observation orders for the first dose.

Why is first-dose hypotension a top ramipril safety concern?

ALTACE labeling warns that excessive blood pressure drops occur most often after the first dose—especially with diuretics, volume depletion, or renal artery stenosis. Post-MI heart failure dosing requires 2.5 mg twice daily with at least two hours of supervised observation after the first dose. Nurses should take orthostatic vitals, monitor urine output, and escalate symptomatic hypotension before giving subsequent doses.

When should nurses hold ramipril?

Hold and contact the prescriber or pharmacist when potassium exceeds protocol limits or ECG changes suggest hyperkalemia, creatinine rises sharply or acute renal failure is suspected, symptomatic hypotension or oliguria occurs—especially with diuretics or volume depletion—pregnancy is confirmed or suspected, angioedema or airway-threatening swelling develops, or known ACE inhibitor hypersensitivity exists.

What happens if pregnancy is detected on ramipril?

Discontinue ramipril as soon as possible per the boxed warning. Drugs acting on the renin-angiotensin system can injure or kill the developing fetus through reduced fetal renal function, oligohydramnios-related complications, and neonatal renal failure.

Is there an antidote for ramipril overdose?

No specific antidote is listed in the reviewed ALTACE prescribing information. Overdosage most likely causes hypotension treated with intravenous normal saline; angiotensin II infusion is theoretically beneficial but is not available. Hemodialysis removal of ramipril is not established per labeling. Consult local poison control or medical toxicology services per facility guidance when ingestion is intentional or dose is uncertain.

Can patients breastfeed while taking ramipril?

ALTACE labeling states that ramipril should not be used in nursing mothers because of potential for serious adverse reactions in breastfed infants. LactMed notes limited human data and recommends alternative agents when possible—individualized prescriber discussion remains required when breastfeeding cannot be avoided.

📚

References

🔐

Review and transparency

This medication guide is written and reviewed using NurseOnShift editorial and pharmacist review standards.

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.

Ramipril: Nursing Drug Guide, First-Dose Hypotension & NCLEX Review

📋 Contents

⚡ Quick facts

💡 Key takeaway

Most common brand names

Why we give it — Indications

How it works

Dosing overview

Onset, peak, duration, and half-life

Before you give it — Safety check

Pretreatment checks

Contraindications (FDA label summary)

Important interactions

Administration

Expected therapeutic response

Red flags — Stop and act

Adverse effects

Overdose management

Recommended supportive therapies (label)

Look-alike / sound-alike and error prevention

Practical bedside notes

High-risk populations

Monitoring and documentation

Monitor

Document

Patient teaching

The Hold Rule

Clinical practice integration and workflow

1. Stewardship checkpoints

2. High-alert designation

3. Hold and question cues

Teach-back prompts

🧠 Quick mental checklist

Ramipril NCLEX practice questions

Answer key & rationale

Frequently asked questions

What should I check before giving ramipril?

Why is first-dose hypotension a top ramipril safety concern?

When should nurses hold ramipril?

What happens if pregnancy is detected on ramipril?

Is there an antidote for ramipril overdose?

Can patients breastfeed while taking ramipril?

References

Related Topics

Hypertension symptoms

Hydrochlorothiazide

Enalapril

Chronic kidney disease

Orthostatic blood pressure

Stroke

Review and transparency